APLLTD

Alembic Pharmaceuticals Ltd.

NSE: APLLTD

BSE: 533573

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

811.30-18.0 (-2.18%)

8 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

76.8 / 100

Value Score

63.2 / 100

Price Momentum Score

46.5 / 100

QVM Score

73.0 / 100

Key Metrics

Market Cap

15947.20

P/E (TTM)

23.63

P/B

2.81

P/S (TTM)

2.17

EV/EBITDA

15.35

CAPE (5Y)

29.13

ROE (TTM)

12.42

ROCE (TTM)

11.81

ROA (TTM)

8.16

Avg 3Y ROE

12.49

Earnings 3Y CAGR

25.43

Sales 3Y CAGR

9.12

Sales 5Y CAGR

6.37

Debt/Equity

0.25

Consensus TP

900.00

Strong Buy %

33.33

Promoter Holding

69.74

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Alembic Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Stock is reasonably valued and PE TTM is at a discount to industry median

PE TTM of 23.63 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -22.19%

What is P/E Ratio?

Median: 30.37

Value 23.63

-215.443255.34

Moderate EPS growth and above median growth of industry

The company delivered moderate EPS growth of 15.66% for 12-month ended 31 Mar 2026 and the growth was 7.54 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.25 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.01 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 5 financial years

What is Dividend streak?

Negative

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -10.3% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Neutral

Moderate and stable ROE

The company reported moderate ROE of 12.42% for 12-month ended 31 Mar 2026 and ROE improved marginally by 75 bps from 1 year ago

What is ROE (FY)?

Moderate and stable operating margin

The company reported moderate operating margin of 10.89% for 12-month ended 31 Mar 2026 and operating margin declined marginally by -5 bps from 1 year ago

What is Operating profit margin?

Moderate revenue growth and in line with median growth of industry

The company delivered moderate revenue growth of 10.08% for 12-month ended 31 Mar 2026 and the growth was 1.16 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.24

Value 10.08

-82.35114662

Company's earnings are of moderate quality

Earnings quality score of 63.1 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

63.1 / 100

Moderate dividend yield

The company has a moderate dividend yield of 1.36%

What is Dividend yield?

Financial Snapshot

See detailed analysis

Multi-year trends for Alembic Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Alembic Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Alembic Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	72.97	72.97	69.77	69.78	69.48	69.48	69.48	69.48	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.61	69.67	69.67	69.74	69.74	69.74
Indian Promoter	72.44	72.44	69.26	69.27	68.97	68.97	68.97	68.97	69.10	69.10	69.10	69.10	69.10	69.10	69.10	69.10	69.10	69.10	69.10	69.10	69.16	69.16	69.23	69.23	69.23
Foreign Promoter	0.53	0.53	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51	0.51
Institutions	15.15	14.40	16.46	17.10	17.53	17.66	16.94	17.50	17.76	18.09	17.87	17.75	17.86	17.99	18.72	19.02	19.84	19.79	19.99	20.23	20.37	20.42	20.35	20.41	20.43
Mutual Funds / UTI	5.00	4.98	6.28	5.77	4.34	4.26	4.44	4.96	5.18	5.01	5.36	5.87	6.47	6.64	7.33	7.71	7.82	8.05	8.90	8.96	9.20	9.05	8.55	8.22	8.18
FI/Bank/Insurance	1.83	2.04	3.09	4.29	6.59	6.92	6.93	6.61	6.52	7.05	7.07	6.64	6.59	6.77	6.60	6.55	7.13	7.01	6.74	6.73	6.91	7.04	7.43	7.64	7.71
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	8.29	7.30	7.03	6.96	6.56	6.41	5.52	5.89	6.02	5.94	5.32	4.99	4.55	4.34	4.51	4.52	4.46	4.32	3.94	4.17	3.94	3.96	4.05	4.23	4.26
Other Institutions	0.04	0.08	0.08	0.09	0.05	0.08	0.05	0.04	0.04	0.09	0.12	0.25	0.26	0.24	0.29	0.25	0.44	0.41	0.41	0.36	0.32	0.37	0.32	0.31	0.28
Non-Institution	11.88	12.63	13.76	13.12	12.99	12.86	13.58	13.03	12.63	12.30	12.52	12.64	12.53	12.40	11.67	11.37	10.54	10.60	10.40	10.16	9.96	9.90	9.92	9.86	9.83
Bodies Corporate	0.72	0.44	0.48	0.41	0.47	0.36	0.39	0.36	0.41	0.46	0.41	0.42	0.41	0.39	0.41	0.38	0.30	0.30	0.18	0.17	0.16	0.17	0.18	0.17	0.16
Others (incl. Retail) No. of shareholders	11.16 46,726	12.19 63,659	13.28 93,163	12.71 90,314	12.52 99,071	12.50 1,01,015	13.19 1,22,396	12.67 1,09,368	12.22 1,05,792	11.84 1,00,830	12.11 1,03,169	12.22 1,01,223	12.12 98,884	12.01 96,986	11.26 88,921	10.99 84,656	10.24 75,975	10.30 74,220	10.22 90,785	9.99 93,299	9.80 90,764	9.73 88,457	9.74 89,381	9.69 86,441	9.67 85,873

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Microcap 250	0.49%	63 / 250
2	Nifty Total Market	0.02%	514 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Alembic Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Nirayu Private Limited Promoter Group	June-2026	Market Purchase (Acquisition) 19th Jun 2026	35.78 %	₹ 743.49	3.28 k	₹ 24.37 lac
Nirayu Private Limited Promoter Group	May-2026	Market Purchase (Acquisition) 25th May 2026	35.65 %	₹ 0.00	6000060000000.00 cr	₹ 4.55 cr
Nirayu Private Limited Promoter Group	October-2025	Market Purchase (Acquisition) 1st Oct 2025	35.64 %	₹ 903.55	10.00 k	₹ 90.35 lac
Nirayu Private Limited Promoter Group	September-2025	Market Purchase (Acquisition) 29th Sep 2025	35.64 %	₹ 901.78	5.00 k	₹ 45.09 lac
Chirayu Ramanbhai Amin HUF Promoter Group	September-2025	Market Purchase (Acquisition) 29th Sep 2025	0.47 %	₹ 925.37	15.00 k	₹ 1.39 cr
Chirayu Ramanbhai Amin HUF Promoter Group	September-2025	Market Purchase (Acquisition) 17th Sep 2025	0.47 %	₹ 962.23	5.20 k	₹ 50.04 lac
Chirayu Ramanbhai Amin HUF Promoter Group	September-2025	Market Purchase (Acquisition) 11th Sep 2025	0.46 %	₹ 959.34	25.00 k	₹ 2.40 cr
Chirayu Ramanbhai Amin HUF Promoter Group	September-2025	Market Purchase (Acquisition) 9th Sep 2025	0.45 %	₹ 948.05	20.00 k	₹ 1.90 cr
Chirayu Ramanbhai Amin HUF Promoter Group	September-2025	Market Purchase (Acquisition) 5th Sep 2025	0.44 %	₹ 963.49	13.07 k	₹ 1.26 cr
Chirayu Ramanbhai Amin HUF Promoter Group	September-2025	Market Purchase (Acquisition) 3rd Sep 2025	0.43 %	₹ 955.98	20.00 k	₹ 1.91 cr

…

Corporate Actions

History of Alembic Pharmaceuticals Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 11/share
Record date: 29th Jul 2025Ex-date: 29th Jul 2025
Announced on: 6th May 2025
Dividend₹ 11/share
Record date: 15th Jul 2024Ex-date: 15th Jul 2024
Announced on: 9th May 2024
Dividend₹ 8/share
Record date: 28th Jul 2023Ex-date: 28th Jul 2023
Announced on: 5th May 2023
Dividend₹ 10/share
Record date: 18th Aug 2022Ex-date: 17th Aug 2022
Announced on: 2nd May 2022
Dividend₹ 14/share
Record date: 20th Jul 2021Ex-date: 19th Jul 2021
Announced on: 4th May 2021

Company Profile

Overview of Alembic Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chr...

Key personnel

G. Krishnan

Chief Financial Officer

Ms. Manisha Saraf

Compliance Officer, Company Secretary

Mr. Chirayu R. AminD

Executive Chairman of the Board

Shri. Pranav Chirayu AminD

Managing Director, Executive Director

Mr. Shaunak AminD

Managing Director, Executive Director

Mr. Raj Kumar BahetiD

Non-Executive Non-Independent Director

Mr. Ashok Kumar Barat, CPAD

Non-Executive Independent Director

Mr. Sujit Jaysukh BhayaniD

Additional Non-Executive Independent Director

View all

Incorporated on

16 Jun 2010

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

17 Sep 2011

Free Float

5,75,99,526

Website

https://alembicpharmaceuticals.com

Phone no.

+912652280550

Address

Alembic Road, VADODARA, 390003, India

Frequently Asked Questions

What is the current share price of Alembic Pharmaceuticals Ltd.?

The current share price of Alembic Pharmaceuticals Ltd. is ₹ 811.30 as of 8 Jul 2026.

What is the market capitalisation of Alembic Pharmaceuticals Ltd.?

The market capitalisation of Alembic Pharmaceuticals Ltd. stands at ₹ 15,947.20 Cr.

What is the PE ratio of Alembic Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Alembic Pharmaceuticals Ltd. is 23.63 as of the latest trailing twelve months data.

What is the ROE and ROCE of Alembic Pharmaceuticals Ltd.?

Alembic Pharmaceuticals Ltd. has a Return on Equity (ROE) of 12.42% and a Return on Capital Employed (ROCE) of 11.81% as per the latest financial reports.

What is the 52-week high and low of Alembic Pharmaceuticals Ltd.?

The 52-week high of Alembic Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Alembic Pharmaceuticals Ltd.?

The dividend yield of Alembic Pharmaceuticals Ltd. is 1.36% based on the current market price.

What is the FII and DII holding in Alembic Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 4.26%, Domestic Institutional Investors (DII) hold 15.89% and retail/public investors hold 9.67% of Alembic Pharmaceuticals Ltd. shares.

What sector does Alembic Pharmaceuticals Ltd. belong to?

Alembic Pharmaceuticals Ltd. operates in the Healthcare sector. 44.44% of analysts have a Buy or Strong Buy rating on Alembic Pharmaceuticals Ltd. with a consensus target price of ₹ 900.00, implying 10.93% upside from current levels.

What is the beta of Alembic Pharmaceuticals Ltd.?

The beta of Alembic Pharmaceuticals Ltd. is 0.95, indicating its price volatility relative to the broader market. Over the past 1 year, Alembic Pharmaceuticals Ltd. has delivered an absolute return of -21.92%.

What is the RSI of Alembic Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Alembic Pharmaceuticals Ltd. is 59.63, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Alembic Pharmaceuticals Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Alembic Pharmaceuticals Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Holdings and Presence

Stock Analysis

Company Profile

Corporate Actions